Cefaclor
(Synonyms: 头孢克洛) 目录号 : GC65613
A cephalosporin antibiotic
Cas No.:53994-73-3
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >99.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Cefaclor is a cephalosporin antibiotic that is active against S. pyogenes, S. pneumoniae, S. aureus, P. mirabilis, S. typhi, E. coli, and H. influenzae (MICs = 0.25, 0.25-2, 1-2, 1, 0.5, 1, and 2-4 μg/ml, respectively).1 It is protective against S. pyogenes, S. pneumoniae, S. aureus, P. mirabilis, S. typhi, E. coli, and H. influenzae infections in mice (ED50s = 0.08-30.2 mg/kg). Formulations containing cefaclor have been used in the treatment of various bacterial infections.
1.Preston, D.A.Summary of laboratory studies on the antibacterial activity of cefaclorInfection7(Suppl. 6)557-561(1979)
| Cas No. | 53994-73-3 | SDF | Download SDF |
| 别名 | 头孢克洛 | ||
| 分子式 | C15H14ClN3O4S | 分子量 | 367.81 |
| 溶解度 | DMSO : 18.5 mg/mL (50.30 mM; Need ultrasonic and warming) | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.7188 mL | 13.594 mL | 27.188 mL |
| 5 mM | 0.5438 mL | 2.7188 mL | 5.4376 mL |
| 10 mM | 0.2719 mL | 1.3594 mL | 2.7188 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Cefaclor revisited
Clin Ther 2000 Feb;22(2):154-66.PMID:10743978DOI:10.1016/S0149-2918(00)88477-5.
Objective: This paper describes the rationale for choosing Cefaclor for the management of respiratory tract infections. Background: Since 1979, Cefaclor has established a record of efficacy in the management of respiratory tract infections. Factors contributing to the efficacy and tolerability of this drug include its molecular stability, activity against the most prevalent gram-positive and gram-negative respiratory tract pathogens, rapid absorption, >90% bioavailability, and good penetration into respiratory mucosa. After 2 decades of widespread use, this agent remains clinically effective in patients with respiratory tract infections, making it competitive with other cephalosporins and with macrolides and fluoroquinolones, including many newer agents used for respiratory tract infections. Cefaclor extended-release tablets, the newest formulation, retain the positive efficacy and tolerability attributes of immediate-release Cefaclor, varying mainly in the rate of dissolution. The approved indications for extended-release Cefaclor include bacterial bronchitis, pharyngitis, and skin infections. Methods: A MEDLINE search showed that the few adverse effects related to therapy with Cefaclor are usually minor and transient and that drug-drug interactions involving Cefaclor are rare. Conclusions: Multiple clinical trials have shown that extended-release Cefaclor in 375-mg and 500-mg doses BID demonstrates tolerability and efficacy comparable to those of immediate-release Cefaclor 250 mg TID. Extended-release Cefaclor is indicated for BID dosing, which should encourage greater compliance.
Cefaclor into the millennium
J Chemother 1999 Jun;11(3):163-78.PMID:10435677DOI:10.1179/joc.1999.11.3.163.
We review the discovery and development of the cephalosporins and subsequently Cefaclor. Cefaclor is active against a wide range of commonly encountered bacterial pathogens, acting by inhibiting cell wall synthesis. Its in vitro activity compares favourably with other beta-lactam antibiotics. Its pharmacokinetic properties indicate that an 8-hourly dosing schedule is appropriate. In addition a delayed release formulation allowing twice daily dosage has been developed. The efficacy of both formulations of Cefaclor has been verified by many clinical trials. Cefaclor has been widely used in infections of the respiratory tract (including otitis media), urinary tract and soft tissues. The results of therapy are summarized. The low incidence of adverse events is highlighted and the beneficial influence of this on compliance is described. Finally, the pharmaco-economics of Cefaclor are considered.
Evaluation of Cefaclor
Am J Hosp Pharm 1981 Jan;38(1):54-8.PMID:7011003doi
The chemistry, pharmacology, pharmacokinetics, bacterial spectrum, clinical use, dosage, adverse reactions, and dosage forms and cost of Cefaclor are reviewed. Cefaclor, a congener of cephalexin monohydrate, is a new semisynthetic cephalosporin antibiotic. It is well absorbed when given orally on an empty stomach; absorption is delayed by the presence of food. Although metabolism may play a role in the disposition of Cefaclor, elimination is primarily renal. Cefaclor's spectrum of activity is similar to that of cefalexin, including a wide range of gram-negative and gram-positive bacteria; in particular, Escherichia coli, Klebsiella spp., Proteus mirabilis, Salmonella spp., and Haemophilus influenzae are more susceptible to clinically achievable concentrations of Cefaclor than cephalexin. Cefaclor has been demonstrated to be effective against beta-lactamase-producing H. influenzae resistant to ampicillin, but further studies are needed to establish the clinical significance of this activity. Efficacy of Cefaclor has been demonstrated in urinary tract, upper and lower respiratory tract, and skin and soft tissue infections in adults and children as well as in pediatric otitis media. Adverse reactions, mostly gastrointestinal, are generally mild and occur in few patients. Usual doses are 250-500 mg every eight hours in adults and 20--40 mg/kg/day in children, although this pediatric dose may be two low for otitis media. Clinical superiority of Cefaclor over less expensive antibiotics has not been demonstrated.
Cefaclor-associated serum sickness-like disease: eight cases and review of the literature
Ann Pharmacother 1992 Jul-Aug;26(7-8):910-4.PMID:1504397DOI:10.1177/106002809202600708.
Objective: To describe the clinical features of serum sickness-like diseases (SSLD) in cefaclor-treated patients. Design: Analysis of a case series spontaneously reported to Lyons Pharmacovigilance Center. Setting: General and hospital practitioners and the French Network of Regional Pharmacovigilance Centers (FNRPC). Patients: All reported cases with a possible causative relationship between Cefaclor treatment and SSLD. Main results: Eight cases of SSLD following Cefaclor treatment are described. The clinical features included cutaneous reactions, arthralgias, and moderate hyperthermia. In 50 percent of the patients, hospitalization was required because of incapacitating symptoms. The outcome was benign in all cases following discontinuation of the offending drug. All eight cases were reported in children under five years of age. Among 137 cefaclor-associated drug reactions collected by FNRPC, 27 cases of SSLD have been reported; 23 of these patients were younger than five years of age. A literature survey confirmed the higher reporting of SSLD in children with Cefaclor compared with other antibiotics and suggested an incidence of 0.024-0.2 percent of SSLD per drug course of Cefaclor. Conclusions: The case reports and epidemiologic studies confirmed the presumed role of age (patients under five years of age) in cefaclor-induced SSLD and the benign outcome despite severe clinical presentations in some reports.
Pharmacokinetic profile of Cefaclor
Int J Clin Pharmacol Ther 1997 Sep;35(9):374-80.PMID:9314090doi
Cefaclor is a well-absorbed oral cephalosporin antibiotic. Peak concentrations in serum are attained within 30-60 minutes. Food intake reduces the rate, but not the extent of absorption. Cefaclor is not metabolized to a significant degree, but it degrades chemically in the body with an approximate half-life of 2 hours. Most of the drug is excreted unchanged in the urine, the serum half-life after oral administration is 0.5-0.7 hours. Due to the chemical degradation, Cefaclor does not accumulate to the same degree as other cephalosporins in case of renal impairment.